MA50609A - Énantiomères de thiazoles substitués utilisés comme composés antiviraux - Google Patents

Énantiomères de thiazoles substitués utilisés comme composés antiviraux

Info

Publication number
MA50609A
MA50609A MA050609A MA50609A MA50609A MA 50609 A MA50609 A MA 50609A MA 050609 A MA050609 A MA 050609A MA 50609 A MA50609 A MA 50609A MA 50609 A MA50609 A MA 50609A
Authority
MA
Morocco
Prior art keywords
enantiomers
antiviral compounds
substituted thiazoles
thiazoles used
substituted
Prior art date
Application number
MA050609A
Other languages
English (en)
Other versions
MA50609B1 (fr
Inventor
Christian Gege
Gerald Kleymann
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of MA50609A publication Critical patent/MA50609A/fr
Publication of MA50609B1 publication Critical patent/MA50609B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA50609A 2017-10-05 2018-10-04 Énantiomères de thiazoles substitués utilisés comme composés antiviraux MA50609B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17195047 2017-10-05
PCT/EP2018/077022 WO2019068817A1 (fr) 2017-10-05 2018-10-04 Énantiomères de thiazoles substitués utilisés comme composés antiviraux

Publications (2)

Publication Number Publication Date
MA50609A true MA50609A (fr) 2020-08-12
MA50609B1 MA50609B1 (fr) 2023-03-31

Family

ID=60022026

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50609A MA50609B1 (fr) 2017-10-05 2018-10-04 Énantiomères de thiazoles substitués utilisés comme composés antiviraux

Country Status (37)

Country Link
US (4) US11278534B2 (fr)
EP (2) EP3692039B1 (fr)
JP (1) JP7215689B2 (fr)
KR (1) KR102708082B1 (fr)
CN (1) CN111433203B (fr)
AR (1) AR113344A1 (fr)
AU (1) AU2018344471B2 (fr)
CA (1) CA3077397A1 (fr)
CL (1) CL2020000869A1 (fr)
CR (1) CR20200154A (fr)
DK (1) DK3692039T3 (fr)
EA (1) EA202090620A1 (fr)
EC (1) ECSP20021132A (fr)
ES (1) ES2939652T3 (fr)
FI (1) FI3692039T3 (fr)
HR (1) HRP20230158T1 (fr)
HU (1) HUE061307T2 (fr)
IL (1) IL273681B2 (fr)
JO (1) JOP20200110B1 (fr)
LT (1) LT3692039T (fr)
MA (1) MA50609B1 (fr)
MD (1) MD3692039T2 (fr)
MX (1) MX2020003369A (fr)
MY (1) MY202544A (fr)
NI (1) NI202000025A (fr)
PH (1) PH12020550132A1 (fr)
PL (1) PL3692039T3 (fr)
PT (1) PT3692039T (fr)
RS (1) RS64000B1 (fr)
SG (1) SG11202002420SA (fr)
SI (1) SI3692039T1 (fr)
SM (1) SMT202300080T1 (fr)
TW (1) TWI706941B (fr)
UA (1) UA126163C2 (fr)
UY (1) UY37917A (fr)
WO (1) WO2019068817A1 (fr)
ZA (1) ZA202002150B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3692039T3 (pl) * 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
AU2021367976A1 (en) 2020-10-29 2023-06-08 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds
PY2302301A (es) * 2022-01-17 2023-10-31 Innovative Molecules Gmbh Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas
EP4580601A1 (fr) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Compositions pharmaceutiques contre le virus de l'herpès
WO2024049760A1 (fr) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Composés de thiazolyl-urée cyclique pour le traitement du vhs
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
KR20260116185A (ko) 2023-11-22 2026-07-28 어셈블리 바이오사이언시스, 인크. 헤르페스 바이러스(hsv) 치료용 아제티딘 화합물
US20260014154A1 (en) 2024-07-12 2026-01-15 Assembly Biosciences, Inc. Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy
WO2026035899A1 (fr) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Composés d'azétidine pour le traitement du hsv
WO2026035901A1 (fr) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Composés tricycliques pour le traitement du vhs
WO2026035900A1 (fr) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Composés tricycliques pour le traitement du hsv
WO2026078039A1 (fr) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Formes d'inhibiteurs antiviraux d'hélicase-primase pour administration orale
CN121873064A (zh) * 2024-10-17 2026-04-17 博远医药(苏州)有限公司 杂环类衍生物及其药物组合物和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2075560A5 (fr) 1970-01-16 1971-10-08 Shell Int Research
NZ331104A (en) 1995-12-29 2000-03-27 Boehringer Ingelheim Ca Ltd Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
ATE229945T1 (de) 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
US6500817B1 (en) 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
EP1319185A1 (fr) 2000-06-15 2003-06-18 Bayer Aktiengesellschaft Methodes d'identification de composes presentant une activite antiherpes
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10129715A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8548554B2 (en) 2006-12-08 2013-10-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Dry electrode cap for electro-encephalography
DE102010046720A1 (de) 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
CN103269593A (zh) * 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2573086A1 (fr) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG Monohydrate de mesylate acétamide N-[5-(Aminosulfonyl)-4-méthyl-1,3-thiazol-2-yl]-N-méthyl-2-[4-(2-pyridinyl)phényl]
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
ES2877854T3 (es) 2016-11-28 2021-11-17 Aicuris Gmbh & Co Kg Una sal de maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, procedimientos de fabricación y usos de las mismas para el tratamiento de los virus del herpes
TW201825095A (zh) 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
TWI811800B (zh) 2016-11-28 2023-08-11 德商艾庫瑞斯公司 N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺游離鹼半水合物、製造方法及其用途
WO2018127207A1 (fr) 2017-01-09 2018-07-12 南京明德新药研发股份有限公司 Dérivé thiazole et utilisations de ce dernier
PL3692039T3 (pl) * 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe

Also Published As

Publication number Publication date
NI202000025A (es) 2020-07-31
WO2019068817A1 (fr) 2019-04-11
AU2018344471A1 (en) 2020-04-09
EP3692039B1 (fr) 2022-12-14
TW201927758A (zh) 2019-07-16
ECSP20021132A (es) 2020-07-31
ZA202002150B (en) 2022-10-26
SI3692039T1 (sl) 2023-04-28
US12527778B2 (en) 2026-01-20
US12295945B2 (en) 2025-05-13
SG11202002420SA (en) 2020-04-29
TWI706941B (zh) 2020-10-11
EP4209491A1 (fr) 2023-07-12
BR112020006710A2 (pt) 2022-11-08
CN111433203A (zh) 2020-07-17
MY202544A (en) 2024-05-07
IL273681A (en) 2020-05-31
MA50609B1 (fr) 2023-03-31
US11278534B2 (en) 2022-03-22
AR113344A1 (es) 2020-04-22
RS64000B1 (sr) 2023-03-31
EA202090620A1 (ru) 2020-07-10
US20260137669A1 (en) 2026-05-21
IL273681B2 (en) 2025-01-01
FI3692039T3 (fi) 2023-03-23
US20240316021A1 (en) 2024-09-26
HUE061307T2 (hu) 2023-06-28
MD3692039T2 (ro) 2023-05-31
US20200289486A1 (en) 2020-09-17
CA3077397A1 (fr) 2019-04-11
PT3692039T (pt) 2023-03-07
ES2939652T3 (es) 2023-04-25
CR20200154A (es) 2020-05-24
LT3692039T (lt) 2023-03-27
UA126163C2 (uk) 2022-08-25
CN111433203B (zh) 2024-02-13
HRP20230158T1 (hr) 2023-03-31
PL3692039T3 (pl) 2023-04-17
MX2020003369A (es) 2020-07-29
CL2020000869A1 (es) 2020-09-21
JOP20200110A1 (ar) 2020-05-07
PH12020550132A1 (en) 2021-02-08
JP2020536108A (ja) 2020-12-10
KR20200066619A (ko) 2020-06-10
JP7215689B2 (ja) 2023-01-31
UY37917A (es) 2019-04-30
IL273681B1 (en) 2024-09-01
EP3692039A1 (fr) 2020-08-12
JOP20200110B1 (ar) 2024-12-22
DK3692039T3 (da) 2023-03-13
KR102708082B1 (ko) 2024-09-19
SMT202300080T1 (it) 2023-05-12
US20220152008A1 (en) 2022-05-19
AU2018344471B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
EP3402799A4 (fr) Composés hétérocycliques utilisés comme inhibiteurs du vrs
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
EP3956033A4 (fr) Composés bicycliques
ZA202002150B (en) Enantiomers of substituted thiazoles as antiviral compounds
MA45116A (fr) Composés hétérocycliques comme immunomodulateurs
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
EP3322409A4 (fr) Composés aza substitués comme inhibiteurs de l'irak-4
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3389783A4 (fr) Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
EP3331880A4 (fr) Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques
EP3727401A4 (fr) Composés dinucléotidiques cycliques utilisés comme agonistes sting
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA45918A (fr) Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3319966A4 (fr) Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
EP3386952A4 (fr) Composés de benzimidazolium, pyrido-imidazolium ou pyrazino-imidazolium substitués utilisés comme agents chimiothérapeutiques
EP3490553A4 (fr) Utilisations de composés d'indolinone
EP3509587A4 (fr) Composés monocycliques utiles comme modulateurs de gpr120
MA50537A (fr) Composés deutérés utilisés comme immunomodulateurs
EP3638237A4 (fr) Composés aminothiazoles utilisés comme inhibiteurs de protéine kinase